GeneThera, Inc. (GTHR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GeneThera, Inc. (GTHR) trades at $0.0001 with AI Score 44/100 (Grade C). GeneThera, Inc. is a biotechnology company focused on developing molecular assays and therapeutics for zoonotic diseases. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for GTHR: GTHR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GTHR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GTHR: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
GeneThera, Inc. (GTHR) Healthcare & Pipeline Overview
GeneThera, Inc. is a biotechnology company specializing in the development of molecular assays and therapeutics for zoonotic diseases, leveraging its Molecular Robotic/AI Platform. The company focuses on preventing disease transmission from animals to humans, positioning it within the evolving landscape of infectious disease control.
What Is the Investment Thesis for GTHR?
GeneThera, Inc. presents a high-risk, high-reward investment profile within the biotechnology sector. The company's focus on zoonotic diseases addresses a growing global concern, particularly in light of recent pandemics. A key value driver is the potential success of its paratuberculosis (Johne's disease) treatment, currently in Stage III clinical trials. Positive trial outcomes could lead to significant revenue generation and market validation. However, the company's small size, limited resources, and OTC market listing introduce substantial risks. Successful commercialization of its products and securing additional funding are critical for long-term viability. The company's beta of 0.81 suggests lower volatility than the overall market, but this may not fully reflect the inherent risks of a micro-cap biotechnology company.
Based on FMP financials and quantitative analysis
GTHR Key Highlights
Focus on zoonotic diseases addresses a growing global health concern.
- Paratuberculosis (Johne's disease) treatment in Stage III clinical trials represents a near-term catalyst.
- Molecular Robotic/AI Platform offers potential for rapid development of new assays and therapeutics.
- Small market capitalization of $0.00B indicates high growth potential but also significant risk.
- Based in Westminster, Colorado, positioning it within a growing biotechnology hub.
Who Are GTHR's Competitors?
GTHR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GTHR's Key Strengths?
Proprietary Molecular Robotic/AI Platform.
- Treatment for paratuberculosis in Stage III clinical trials.
- Focus on a growing market for zoonotic disease solutions.
- Development of vaccine for mycobacterium avium sub paratuberculosis.
What Are GTHR's Weaknesses?
Small size and limited resources.
- OTC market listing indicates higher risk.
- Dependence on successful clinical trials and regulatory approvals.
- Limited commercialization experience.
What Could Drive GTHR Stock Higher?
Completion of Stage III clinical trials for paratuberculosis (Johne's disease) treatment by Q4 2026.
- Development of new molecular assays for emerging zoonotic diseases.
- Pursuit of strategic partnerships and collaborations with pharmaceutical companies.
- Securing additional funding to support research and development activities.
What Are the Key Risks for GTHR?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure of clinical trials for paratuberculosis treatment.
- Inability to secure additional funding.
- Competition from larger, more established biotechnology companies.
- Regulatory hurdles and lengthy approval processes.
- Limited liquidity due to OTC market listing.
What Are the Growth Opportunities for GTHR?
- Expansion of Molecular Robotic/AI Platform: GeneThera's Molecular Robotic/AI Platform offers a significant growth opportunity by enabling rapid development of new molecular assays and therapeutics for a wide range of zoonotic diseases. The market for molecular diagnostics is projected to reach $14 billion by 2028, driven by increasing demand for rapid and accurate disease detection. Successful expansion of the platform could lead to strategic partnerships and licensing agreements, generating substantial revenue streams for GeneThera.
- Commercialization of Paratuberculosis (Johne's disease) Treatment: The company's treatment for paratuberculosis (Johne's disease), currently in Stage III clinical trials, represents a significant near-term growth opportunity. Johne's disease affects livestock populations worldwide, causing significant economic losses for farmers. Successful commercialization of the treatment could capture a substantial share of the veterinary pharmaceutical market, estimated at $35 billion globally. The timeline for commercialization depends on the successful completion of clinical trials and regulatory approval.
- Development of Vaccine for Mycobacterium Avium Sub Paratuberculosis: GeneThera's development of a vaccine for mycobacterium avium sub paratuberculosis bacteria presents a long-term growth opportunity. A successful vaccine could prevent the spread of Johne's disease, reducing economic losses for farmers and improving animal health. The global animal vaccine market is projected to reach $12 billion by 2027, driven by increasing demand for preventative healthcare solutions for livestock. The timeline for vaccine development and commercialization is typically several years, requiring significant investment and clinical trials.
- Strategic Partnerships and Collaborations: GeneThera can pursue strategic partnerships and collaborations with larger pharmaceutical companies, research institutions, and government agencies to accelerate the development and commercialization of its products. Collaborations can provide access to funding, expertise, and distribution networks, enhancing the company's competitive position. The market for biotechnology collaborations is highly active, with numerous deals announced each year. Successful partnerships could significantly increase GeneThera's visibility and market reach.
- Expansion into New Geographic Markets: GeneThera can expand its geographic reach by targeting new markets with high prevalence of zoonotic diseases. Emerging markets in Asia and Africa represent significant growth opportunities due to increasing livestock populations and limited access to advanced diagnostic and therapeutic solutions. The global veterinary healthcare market is experiencing rapid growth in these regions, driven by rising incomes and increasing awareness of animal health. Successful expansion into new markets could diversify GeneThera's revenue streams and reduce its reliance on specific geographic regions.
What Are GTHR's Competitive Advantages?
- Proprietary Molecular Robotic/AI Platform for rapid assay development.
- Patented therapeutics for specific zoonotic diseases.
- Stage III clinical phase treatment for paratuberculosis (Johne's disease).
- Expertise in zoonotic disease detection and treatment.
What Does GTHR Do?
GeneThera, Inc., founded to address the growing threat of zoonotic diseases, operates as a biotechnology company focused on developing innovative molecular assays and therapeutics. The company's core mission is to prevent the spread of diseases from animals to humans, leveraging its proprietary Molecular Robotic/AI Platform and Therapeutic strategy. GeneThera's product pipeline includes treatments for a range of zoonotic diseases, including COVID-19, paratuberculosis (Johne's disease) currently in Stage III clinical phase, mad cow and chronic wasting diseases, and E.coli and salmonella infections. Additionally, the company is developing a vaccine for mycobacterium avium sub paratuberculosis bacteria. Based in Westminster, Colorado, GeneThera aims to provide better control of zoonotic infectious agents through its integrated platform and therapeutic solutions. The company's approach combines advanced molecular diagnostics with targeted therapeutic interventions to address the complex challenges posed by zoonotic diseases. GeneThera's focus on early detection and prevention aligns with the increasing global emphasis on proactive disease management and public health preparedness.
What Products and Services Does GTHR Offer?
- Develops molecular assays for the detection of zoonotic diseases.
- Creates therapeutics for the treatment of zoonotic diseases.
- Offers treatments for COVID-19 disease.
- Provides solutions for paratuberculosis (Johne's disease).
- Develops treatments for mad cow and chronic wasting diseases.
- Offers solutions for E.coli and salmonella infections.
- Develops vaccines for mycobacterium avium sub paratuberculosis bacteria.
- Utilizes a Molecular Robotic/AI Platform for disease control.
How Does GTHR Make Money?
- Develops and sells molecular assays for detecting zoonotic diseases.
- Creates and markets therapeutics for treating zoonotic infections.
- Partnerships with veterinary clinics and research institutions.
- Out-licensing of proprietary technologies.
What Industry Does GTHR Operate In?
The biotechnology industry is characterized by high growth potential and intense competition. Companies like GeneThera, Inc. operate within a landscape driven by innovation, regulatory hurdles, and significant capital requirements. The increasing prevalence of zoonotic diseases, coupled with growing awareness of pandemic risks, has created a heightened demand for effective diagnostic and therapeutic solutions. GeneThera's focus on this niche positions it within a segment experiencing rapid growth, but also requires it to compete with larger, more established players in the biotechnology space. The company's success will depend on its ability to navigate the complex regulatory environment, secure funding, and effectively commercialize its products.
Who Are GTHR's Key Customers?
- Veterinary clinics and hospitals.
- Livestock farmers and ranchers.
- Research institutions studying zoonotic diseases.
- Government agencies involved in public health and disease control.
How GeneThera, Inc. Is Valued
Relative to its peer group, GTHR's quantitative score of 44/100 is below the peer average of 76/100.
Company Profile
GeneThera, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Westminster, US. The company is led by CEO Antonio Milici. GTHR has traded publicly since 2012.
Key Financial Metrics
Return on equity for GeneThera, Inc. stands at 12.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
GeneThera, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
GTHR Financials
Bull Case vs Bear Case
Bull Case
- Proprietary Molecular Robotic/AI Platform.
- Treatment for paratuberculosis in Stage III clinical trials.
- Focus on a growing market for zoonotic disease solutions.
- Development of vaccine for mycobacterium avium sub paratuberculosis.
Bear Case
- Small size and limited resources.
- OTC market listing indicates higher risk.
- Dependence on successful clinical trials and regulatory approvals.
- Limited commercialization experience.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
GTHR Latest News
No recent news available for GTHR.
GTHR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GTHR.
Price Targets
Wall Street price target analysis for GTHR.
GTHR MoonshotScore
What does this score mean?
The MoonshotScore rates GTHR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Antonio Milici
CEO
Antonio Milici serves as the CEO of GeneThera, Inc., leading the company's efforts in developing molecular assays and therapeutics for zoonotic diseases. With a background in biotechnology and management, Milici is responsible for overseeing the company's strategic direction, research and development activities, and overall operations. His experience includes managing small teams and driving innovation in the biotechnology sector. Milici's leadership is focused on advancing GeneThera's pipeline of products and expanding its market reach.
Track Record: Under Antonio Milici's leadership, GeneThera, Inc. has focused on advancing its paratuberculosis (Johne's disease) treatment to Stage III clinical trials. He has overseen the development and implementation of the company's Molecular Robotic/AI Platform. Milici has also been responsible for securing funding and establishing strategic partnerships to support the company's growth initiatives. His tenure has been marked by a commitment to addressing the growing threat of zoonotic diseases.
GTHR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that GeneThera, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure and regulatory oversight.
- Low trading volume and liquidity.
- Potential for price manipulation and volatility.
- Higher risk of fraud or mismanagement.
- Difficulty in obtaining accurate and timely information.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Monitor news and press releases for any red flags.
- Consult with a qualified financial advisor.
- Focus on addressing a real-world problem (zoonotic diseases).
- Development of a proprietary Molecular Robotic/AI Platform.
- Advancement of paratuberculosis treatment to Stage III clinical trials.
- Company is based in the United States.
- CEO has a background in biotechnology.
GeneThera, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for GTHR?
GTHR holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. GeneThera, Inc. is a biotechnology company focused on developing molecular assays and therapeutics for zoonotic diseases. Their platform aims to prevent the spread of diseases from animals to humans.
What does GeneThera, Inc. do?
GeneThera, Inc. is a biotechnology company focused on developing molecular assays and therapeutics for the detection and treatment of zoonotic diseases. The company's core mission is to prevent the spread of diseases from animals to humans. GeneThera utilizes its proprietary Molecular Robotic/AI Platform to develop solutions for diseases like COVID-19, paratuberculosis (Johne's disease), mad cow disease, and E.coli infections.
What are the main risks for GTHR?
GeneThera, Inc. faces several significant risks, including the potential failure of clinical trials for its paratuberculosis treatment, which is a key near-term catalyst. The company's limited financial resources and OTC market listing also pose risks related to liquidity and access to capital.
What are the key factors to evaluate for GTHR?
GeneThera, Inc. (GTHR) holds an AI score of 44/100 (low). presents a high-risk, high-reward investment profile within the biotechnology sector. Not financial advice.
How frequently does GTHR data refresh on this page?
GTHR's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven GTHR's recent stock price performance?
GeneThera, Inc. (GTHR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Molecular Robotic/AI Platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GTHR overvalued or undervalued right now?
GeneThera, Inc. (GTHR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GTHR before investing?
Before investing in GeneThera, Inc. (GTHR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GTHR to a portfolio?
Key strength of GeneThera, Inc. (GTHR): Proprietary Molecular Robotic/AI Platform. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data.
- OTC market investments are inherently risky.